Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
47 hedge funds and large institutions have $34.7M invested in Enzo Biochem, Inc. in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 10 closing their positions.
136% more call options, than puts
Call options by funds: $198K | Put options by funds: $84K
10% less funds holding
Funds holding: 52 → 47 (-5)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
44% less capital invested
Capital invested by funds: $61.7M → $34.7M (-$27M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Potomac Capital Management
New York
|
+$624K |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$245K |
| 3 |
FLC
Fifth Lane Capital
Austin,
Texas
|
+$69.8K |
| 4 |
SMA
Sage Mountain Advisors
Atlanta,
Georgia
|
+$54.1K |
| 5 |
CC
Centiva Capital
New York
|
+$45.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$13.6M |
| 2 |
BlackRock
New York
|
-$977K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$589K |
| 4 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$518K |
| 5 |
Morgan Stanley
New York
|
-$239K |
ENZ Hedge Fund Activity: Q2 2023 in Review
47 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q2 2023, worth a combined $34.7M — down 44% from $61.7M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ENZ and 5 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 9 added.
The largest buyer was Potomac Capital Management, adding an estimated $624K. The largest seller was Mirabella Financial Services, exiting entirely with an estimated $13.6M sold.
- 47 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q2 2023, down from 52 in Q1 2023.
- Funds reported $34.7M of Enzo Biochem, Inc. stock for Q2 2023, down 44% quarter-over-quarter.
- 5 funds opened new Enzo Biochem, Inc. positions in Q2 2023 and 10 closed out, a net change of -5 holders.
- The largest Enzo Biochem, Inc. buyer in Q2 2023 was Potomac Capital Management, an estimated $624K added.
- The largest Enzo Biochem, Inc. seller in Q2 2023 was Mirabella Financial Services, an estimated $13.6M sold.
Based on aggregated 13F filings for Q2 2023.